Showing results (201-210 of 214) with videos related to

Sort By:
Pageof 22
Surgery|August 28, 2018
Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemoradiation therapy for pancreatic cancerHidenori Takahashi, Hirofumi Akita, Hiroshi Wada, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|March 13, 2019
Feasibility and Safety of a Novel Laparoscopic and Endoscopic Cooperative Surgery Technique for Superficial Duodenal Tumor Resection: How I Do ItYoshitomo Yanagimoto, Takeshi Omori, Moon Jeong-Ho, et al.
Cancer Chemotherapy and Pharmacology|July 20, 2026
Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysisYoshitomo Yanagimoto, Kazuyoshi Yamamoto, Kei Yamamoto, et al.
Japanese Journal of Clinical Oncology|April 7, 2025
Two cases of protein-losing enteropathy induced by zolbetuximab in patients with unresectable advanced gastric cancerYoshitomo Yanagimoto, Kazuyoshi Yamamoto, Keigo Hara, et al.
BMC Cancer|January 18, 2023
DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancerShinichiro Hasegawa, Hidenori Takahashi, Hirofumi Akita, et al.
Annals of Surgical Oncology|November 11, 2023
Phase II Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 and Cisplatin for Gastric Cancer with Peritoneal MetastasisDaisuke Kobayashi, Yasuhiro Kodera, Ryoji Fukushima, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|March 9, 2020
Decreased CT-number in the pancreatic parenchyma is a reliable imaging biomarker of the presence of malignancies in patients with high-risk intraductal papillary mucinous neoplasmTomoki Abe, Daisaku Yamada, Kei Asukai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2026
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction CancerIzuma Nakayama, Min-Hee Ryu, Sung Hee Lim, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 20, 2024
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trialNarikazu Boku, Takeshi Omori, Kohei Shitara, et al.
The Lancet. Oncology|January 14, 2022
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, et al.
Pageof 22